Intravesical Mitomycin (Zusduri) for Bladder Cancer

Zusduri (UroGen), a mitomycin-based solution for intravesical instillation, has been approved by the FDA for treatment of recurrent low-grade intermediate-risk nonmuscle invasive bladder cancer (NMIBC) in adults. It is the first drug to be approved in the US for this indication. Mitomycin has been available for years for treatment of various malignancies.

Publication Details

Journal: The medical letter on drugs and therapeutics/The medical letter
Published: 2025-08-04
DOI: https://doi.org/10.58347/tml.2025.1734c
Primary Topic: Bladder and Urothelial Cancer Treatments
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Intravesical Mitomycin (Zusduri) for Bladder Cancer

Aug 4, 2025

The medical letter on drugs and therapeutics/The medical letter

Bladder and Urothelial Cancer Treatments

article

Intravesical Mitomycin (Zusduri) for Bladder Cancer

August 4, 2025article en

Abstract

The medical letter on drugs and therapeutics/The medical letterVol. 67(1734)

Good health and well-being

Openalex Percentile: Top 69%

Bladder and Urothelial Cancer Treatments

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Intravesical Mitomycin (Zusduri) for Bladder Cancer · The medical letter on drugs and therapeutics/The medical letter (2025) | TGRS Research Map | TGRS